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ABSTRACT
Introduction: The efficacy of pharmaceuticals is most
often demonstrated by randomised controlled trials
(RCTs); however, in some cases, regulatory
applications lack RCT evidence.
Objective: To investigate the number and type of
these approvals over the past 15 years by the European
Medicines Agency (EMA) and the US Food and Drug
Administration (FDA).
Methods: Drug approval data were downloaded from
the EMA website and the ‘Drugs@FDA’ database for all
decisions on pharmaceuticals published from 1
January 1999 to 8 May 2014. The details of eligible
applications were extracted, including the therapeutic
area, type of approval and review period.
Results: Over the period of the study, 76 unique
indications were granted without RCT results (44 by
the EMA and 60 by the FDA), demonstrating that a
substantial number of treatments reach the market
without undergoing an RCT. The majority was for
haematological malignancies (34), with the next most
common areas being oncology (15) and metabolic
conditions (15). Of the applications made to both
agencies with a comparable data package, the FDA
granted more approvals (43/44 vs 35/44) and took less
time to review products (8.7 vs 15.5 months).
Products reached the market first in the USA in 30 of
34 cases (mean 13.1 months) due to companies
making FDA submission before EMA submissions and
faster FDA review time.
Discussion: Despite the frequency with which
approvals are granted without RCT results, there is no
systematic monitoring of such treatments to confirm
their effectiveness or consistency regarding when this
form of evidence is appropriate. We recommend a
more open debate on the role of marketing
authorisations granted without RCT results, and the
development of guidelines on what constitutes an
acceptable data package for regulators.
INTRODUCTION
The efﬁcacy of pharmaceuticals is usually
evaluated for regulatory purposes using ran-
domised controlled trials (RCTs) that, when
properly designed and conducted, provide un-
biased estimates of treatment effect.1 However,
there are occasions when a therapy is adminis-
tered to all patients within a trial; this is a fre-
quent step in the development process of
pharmaceuticals. While it is not necessarily a
preferred approach, the product can be sub-
mitted to regulatory agencies for approval fol-
lowing these studies. This can occur with
treatments that are new to the market, or for
the extension of a licensed treatment to a dif-
ferent patient population, with the argument
that clinical equipoise no longer applies. As
the treatment is obviously effective, there is no
clinical uncertainty, and as such, to withhold
the treatment from one group in a trial would
be unethical or impractical.2–4
Uncontrolled clinical studies may take
several forms that include aspects of random-
isation (ﬁgure 1). For example, patients may
be randomised to different dosages (or regi-
mens) of the experimental treatment. Other
data packages may include a clinical study
compared to a historical control, such as a
Strengths and limitations of this study
▪ This work is the first systematic attempt to iden-
tify drugs approved without randomised
evidence.
▪ The in-depth review identifies all evidence for
treatments throughout the clinical development
programme, not just the pivotal study.
▪ Because of the different remits and processes of
the European Medicines Agency and the Food
and Drug Administration, it is not possible to
compare across all disease areas.
▪ Despite identifying treatments without rando-
mised evidence, it is not in the scope of this
study to conclude on the appropriateness of
approval on the basis of non-randomised data.
▪ Due to the lack of follow-up studies, it is also
not possible to reach a conclusion on the effi-
cacy of these products.
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previously published study of similar patients treated
with the relevant comparator.5 Finally, other treatments
may have no control arm or control data, but instead
rely on an ‘obvious’ difference, or avoidance of an
expected outcome—for example, death from poisoning.
The common factor in each of these designs is that the
study in isolation is insufﬁcient to demonstrate the
effectiveness of the treatment (ie, external data are
needed) as it does not contain an internal control arm
(either active or placebo) against which outcomes can
be compared.
Following the clinical study programme, the data
package for a treatment is submitted to the regulator,
who must give their approval before a drug is allowed on
the market. In the EU and the USA, there are slightly dif-
ferent paths to approval. Historically, pharmaceutical
licensing in the EU was the responsibility of individual
countries; however, with the development of the cen-
tralised authorisation procedure by the European
Medicines Agency (EMA) in 1995, companies submit a
dossier to the EMA. The EMA reviews the submission,
asks questions to the company as a part of the process,
and then issues a decision that is binding throughout the
EU.6 In the USA, manufacturers submit a New Drug
Application (NDA) to the Food and Drug Administration
(FDA) which will review the data submitted before
making a decision on the request.7
The objective of this study was to review new pharma-
ceutical approvals by the EMA and the FDA, from 1999
to 2014, to understand how frequently applications (and
approvals) are made solely on the basis of uncontrolled
studies, without either the pivotal study or supportive
studies being RCTs in the indication (previous work has
focused solely whether the pivotal study contained a
control arm8). A secondary analysis compared the
approval rates of the EMA and the FDA for evidence of
differences in the approach taken to comparable appli-
cations in approval rate and timing.
METHODS
Details of the trials conducted for the licensing applica-
tion of treatments were identiﬁed through publicly
available regulatory documents. In the case of the EMA,
the main sources of information were the European
Public Assessment Reports and the Committee of
Human Medicinal Products Assessment Reports, while
for the FDA, these were the approved label and the
Medical Ofﬁcer’s report.
All sources were taken directly from the websites of
the EMA and the FDA. The EMA approval database was
downloaded on 8 May 2014 (http://www.ema.europa.
eu/ema/), and the FDA ‘Drugs@FDA’ database was
downloaded on 15 May 2014 (http://www.fda.gov/Drugs/).
These databases were used to explore drug approvals
based on uncontrolled trial results from 1 January 1999
to 8 May 2014. This date range was chosen as it started
several years after the beginning of the EMA Centralised
Procedure (1995), giving time for the process to become
established. Each approval was reviewed in turn to iden-
tify applications made without supportive RCT results.
Following deduplication, all products not approved by
both agencies were searched for individually on the
website of the other agency with no date restriction to
understand whether they were approved before the date
period. Searches were also conducted on the website of
the manufacturer, and in PubMed and Google News for
information regarding submissions, in order to identify
any products that did not appear in the databases use
for the main analysis.
The aim of our study was to look at newly approved
indications for pharmaceuticals, which led to the exclu-
sion of several types of product, listed in table 1.
Applications were compared against the exclusion cri-
teria, and if excluded, the reason for exclusion was
noted in a hierarchical fashion. If a regulatory applica-
tion for a product was made to one agency but did not
appear in the results for the other agency, a search with
no date restriction on was performed to identify any
applications made outside the review window (to ensure
all comparable approvals have been included).
The included data were for each approved indication,
other approved indications for the treatment, submission
and decision dates, disease area and supporting evidence
for the approval.
Figure 1 Types of uncontrolled studies used to support regulatory applications compared to randomised controlled trials.
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RESULTS
From January 1999 to May 2014, the EMA issued 795
approvals, including 44 indications approved solely on
the basis of uncontrolled trials (ﬁgure 2). Of the 44
approvals, 8 were extensions of indications for treat-
ments with RCTs in other approved indications, while
the remaining 36 approvals were for products in which
there were no RCT results in an approved indication.
Over the time period, for nine applications without
supporting RCT results, the EMA rejected the applica-
tion or the manufacturer withdrew its submission with a
negative recommendation in place.
In the same time period, the FDA issued 774 ap-
provals, which included 60 indications approved solely
on the basis of uncontrolled studies (ﬁgure 2). Of the
60 approvals, 12 were extensions of indications for treat-
ments with RCTs in other approved indications, while
the remaining 48 were for products in which there were
no RCT results in an approved indication. Only one
application made without controlled trial results (tem-
porﬁn for head and neck cancer) received was not
approved.
Deduplicating for approvals granted in both regions,
74 indications were approved over the period by at least
one agency on the basis of uncontrolled trials (table 1).
Thirty-four approvals (the largest group) were in haem-
atological oncology, 15 in solid tumour oncology, and 15
in rare metabolic conditions (including enzyme replace-
ment therapies). Outside of these areas, eight approvals
were granted in poisoning or emergency medicine and
two in general haematology. All the approvals that were
extensions of the license for existing therapies were in
either haematological oncology or solid tumour oncology
(table 2).
Searching for treatments approved by only one agency
on the basis of only uncontrolled studies without a date
restriction yielded further four approvals, which was
used in the comparison of EMA and the FDA approval
rates and times. Four treatments approved by the EMA
1999 in our date range were approved prior to 1999 by
the FDA with a similar data package.
For applications made in both regions, 44 applications
were made to both the EMA and the FDA without con-
trolled results (including the 4 made to the FDA prior to
1999), with the EMA approving 35 and the FDA approv-
ing 43. Of the 34 applications approved in both regions,
the EMA approval was granted a mean of 13.4 months
later (median 6.7, IQR 4.5–17.2 months). This delay
consisted of two parts: ﬁrst, companies submitted to the
EMA a mean of 7.4 months later (median 1.5, IQR 0.1–
8 months), with 28 of 34 indications submitted to the
FDA ﬁrst. Second, the EMA took an average of 6.3
months longer to complete their review and approve
products (median 0.2, IQR 0.1–0.3 months); in compar-
able approvals, the EMA review was quicker in only 3 of
34 applications leading to 30/34 products reaching the
market ﬁrst in the USA.
In addition to the EMA approving fewer products
and taking longer to approve products, ﬁve treatments
were approved with only uncontrolled studies by the
FDA, but approved by the EMA at a later date when
comparative results were available (a delay in approval of
21.5 months mean/9 months median).
DISCUSSION
The number of approvals without supporting RCT evi-
dence was in excess of what we had expected, with a
mean of ∼5 indications per year approved by either
(or both) the EMA and the FDA. We had also
expected the majority of approvals to be license
extensions of existing products; however, this was not
the case—only 19% of approvals were license exten-
sions of products demonstrated to be efﬁcacious in
Table 1 Exclusion criteria and rationale
Exclusion criteria Rationale
Generic drugs Licensed on the basis of similarity to existing drugs and would result in duplication
Biosimilar drugs The interpretation of data from trials of biosimilars is likely to be informed by data
available regarding the original drug (in mechanism and effect on a condition). As such
biosimilar applications cannot be considered as comparable to applications for new
drugs for which no external information is available
Diagnostic technologies and
medical devices
As there is no therapeutic effect to measure, these are assessed by different criteria
Vaccines The majority of vaccines are licensed based on well-understood technologies and
mechanisms of action and it is therefore to consider their use in isolation
Antimicrobial products The approval process for antimicrobial products involves different standards, with in
vitro demonstrations of efficacy against different bacteria playing a much larger role in
the expansion of indications
Blood products and recombinant
blood products
If identical to human blood products, the mechanism of action for these products is well
understood, and thus the same efficacy trials to prove the concept of the intervention is
not needed
Fixed dose combinations of
existing products
Unless additional claims are made of the combination product, the evidence base for
these products is influenced by that for the original products
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RCTs in other diseases. Although these approvals
based solely on uncontrolled data are a relatively
small proportion of the total number approvals, in
absolute terms they number ∼3 per year by the EMA
and 4 per year by the FDA and are worthy of further
scrutiny.
The disease areas where uncontrolled studies are used
for approval were primarily in oncology, with 49/74 indi-
cations (66%) being either haematological or solid
tumour oncology. This also corresponds with previous
work regarding drug licensing, which shows a lower
barrier to oncology drug approval.9 This particularly
seems to be the case with FDA reviews; of the nine appli-
cations to the EMA that were not approved, seven were
in oncology, with the EMA highlighting uncertainty
regarding the beneﬁt to the risk ratio of the treatments.
While the perceived unmet need in oncology has been
used as an argument for the use of uncontrolled studies,
we are not aware of a similar discussion in the literature
regarding rare diseases. In addition, it is also possible
that the FDA did not approve other treatments approved
by the EMA, and this was dealt with conﬁdential
letters10 (with no press releases issued by the companies
concerned). While this is unlikely, it remains an unavoid-
able limitation of the study.
While there is a considerable overlap in decisions, it
appears that the FDA is more willing to approve pro-
ducts on the basis of uncontrolled trials. This difference
may reﬂect the systems of approval or the attitudes of
regulators towards risk versus unmet medical need.11 12
Other evidence also shows that the two systems produce
decisions on different timescales, despite access to the
same clinical studies. A difference in approval times has
been seen in the approval of tyrosine kinase inhibitors,13
cancer drugs14 and pharmaceuticals in general15 by the
two agencies. The difference may in part be explained
by the FDA’s extensive use of ‘accelerated approvals’
(results based on a surrogate end point, with conﬁrma-
tory RCTs conducted subsequently16), compared to the
lesser use of the equivalent EMA process, conditional
approval.
The results regarding dates of approvals appear to
show that patients in the EU must wait longer for novel
treatments. The delay in submitting between agencies is
understandable, given that the staff involved (eg, trial
statisticians) may be required to work on submissions for
both agencies. Companies appear to prioritise the FDA
submission, which we have noted but not speculated on.
Initiatives to harmonise the processes (eg, the
Transatlantic Trade and Investment Partnership) may be
helpful in reducing these delays, provided that they do
not have other negative externalities.17
The issue of longer approval times for the EMA is
more complex. The longer process in Europe may be
due to the organisation required for making decisions
for all EU member states (as well as Iceland,
Liechtenstein and Norway). A further potential factor
in the higher non-approval rate by the EMA (9 vs 1
applications of similar content) and the longer review
period is the opportunity for discussion about the
content of applications (and resolution of issues)
before a dossier is submitted. Companies typically
engage after each phase of clinical development with
the FDA, as well as before submitting a New Drug
Application.18 In Europe, companies do not necessarily
interact with the EMA during the course of develop-
ment but may take Scientiﬁc Advice prior to submitting;
however, only 14 of the 34 products approved by both
agencies had done so (Personal communication,
European Medicines Agency).
Figure 2 PRISMA diagrams—drug approvals based on uncontrolled clinical studies by the FDA and the EMA.
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Table 2 Drugs submitted to the EMA and the FDA containing only uncontrolled clinical studies
Generic name Condition Categorisation
EMA
status
FDA
status
RCT results
available
Abarelix Prostate cancer Solid tumour oncology – A No
Alemtuzumab Chronic lymphocytic leukaemia (CLL) Haematological oncology A A No
Alglucosidase alfa Pompe disease Rare metabolic condition A A No
Alipogene tiparvovec Familial lipoprotein lipase deficiency Rare metabolic condition A – No
Anagrelide Essential thrombocytopenia Blood count A A* No
Argatroban Heparin-induced thrombocytopenia Blood count – A* No
Arsenic trioxide Acute promyelocytic leukaemia Haematological oncology A A No
Asparaginase Erwinia
chrysanthemi
Acute lymphoblastic leukaemia (ALL) Haematological oncology – A No
Bendamustine hydrochloride Non-Hodgkin’s lymphoma Haematological oncology – A Yes
Betaine anhydrous Homocystinuria Rare metabolic condition A – No
Bexarotene Cutaneous T-cell lymphoma (CTCL) Solid tumour oncology A A No
Bortezomib Multiple myeloma (MM) Haematological oncology A A No
Bortezomib Mantle cell lymphoma (MCL) Haematological oncology – A Yes
Bosutinib Chronic myeloid leukaemia (CML) Haematological oncology A A Yes
Brentuximab vedotin Hodgkin’s lymphoma (HL) Haematological oncology A A No
Brentuximab vedotin Systemic anaplastic large cell lymphoma (sALCL) Haematological oncology A A No
Busulfan Haematopoietic progenitor cell transplantation (HPCT) Haematological oncology A A Yes
Carfilzomib MM Haematological oncology – A No
Carglumic acid Chronic hyperammonaemia Rare metabolic condition A A No
Ceritinib Non-small cell lung cancer Solid tumour oncology – A No
Cetuximab Colorectal cancer Solid tumour oncology A A No
Cholic acid (Kolbam) Inborn errors in primary bile acid synthesis Rare metabolic condition A – No
Cholic acid (Orphacol) Inborn errors in primary bile acid synthesis Rare metabolic condition A – No
Cladribine Hairy cell leukaemia Haematological oncology A – No
Clofarabine ALL Haematological oncology A A No
Crizotinib Non-small-cell lung cancer Solid tumour oncology – A No
Dasatinib CML Haematological oncology A A No
Dasatinib Philadelphia chromosome-positive ALL Haematological oncology A A No
Defibrotide Veno-occlusive disease Poisoning A – Yes
Dexrazoxane hydrochloride Anthracycline extravasation Poisoning A – No
Ferric hexacyanoferrate (II) Internal contamination with radioactive caesium or thallium Poisoning – A No
Gefitinib Non-small cell lung cancer (NSCLC) Solid tumour oncology – A No
Gemtuzumab ozogamicin Acute myeloid leukaemia (AML) Haematological oncology S S No
Glucarpidase Toxic plasma methotrexate concentrations Poisoning S A No
Hydroxocobalamin Treatment of cyanide poisoning Poisoning A A No
Ibrutinib Mantle cell lymphoma (MCL) Haematological oncology – A No
Ibrutinib CLL Haematological oncology – A No
Imatinib mesylate Chronic myeloid leukaemia (CML) Haematological oncology A A No
Imatinib mesylate Gastrointestinal stromal tumours (GIST) Solid tumour oncology A A No
Continued
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Table 2 Continued
Generic name Condition Categorisation
EMA
status
FDA
status
RCT results
available
Imatinib mesylate Myelodysplastic/myeloproliferative diseases (MDS/MPD)
associated with platelet-derived growth factor receptor (PDGFR)
gene re-arrangements
Haematological oncology A A Yes
Imatinib mesylate Soft tissue sarcoma—Dermatofibrosarcoma protuberans (DFSP) Solid tumour oncology A A Yes
Imatinib mesylate Philadelphia chromosome-positive acute ALL Haematological oncology – A Yes
Imatinib mesylate Aggressive systemic mastocytosis (ASM) Haematological oncology S A Yes
Imatinib mesylate Advanced hypereosinophilic syndrome (HES) and/or chronic
eosinophilic leukaemia (CEL) with FIP1L1-PDGFR
rearrangement
Haematological oncology A A Yes
Ixabepilone Breast cancer Solid tumour oncology S A Yes
Lomitapide mesylate Familial hypercholesterolemia (HoFH) Rare metabolic condition A A No
Metreleptin Lipodystrophy due to leptin deficiency Rare metabolic condition – A No
Nelarabine T-cell acute lymphoblastic leukaemia/lymphoma (T-ALL/T-LBL) Haematological oncology A A No
Nilotinib hydrochloride
monohydrate
Chronic myeloid leukaemia (CML) Haematological oncology A A No
Nitisinone Hereditary tyrosinaemia Rare metabolic condition A A No
Ofatumumab CLL Haematological oncology A A No
Omacetaxine mepesuccinate CML Haematological oncology S A No
Paclitaxel Kaposi’s sarcoma Solid tumour oncology A A Yes
Pasireotide diaspartate Cushing’s disease Rare metabolic condition A A No
Pentetate calcium trisodium Internal contamination with plutonium, americium, or curium Poisoning – A No
Pentetate zinc trisodium Internal contamination with plutonium, americium, or curium Poisoning – A No
Pomalidomide Multiple myeloma (MM) Haematological oncology – A No
Ponatinib hydrochloride CML Haematological oncology A A No
Ponatinib hydrochloride Philadelphia chromosome-positive acute ALL Haematological oncology A A No
Pralatrexate Peripheral T-cell lymphoma (PTCL) Haematological oncology S A No
Raxibacumab Anthrax inhalation Poisoning – A No
Romidepsin Peripheral T-cell lymphoma (PTCL) Haematological oncology S A Yes
Sodium ferric gluconate complex Iron deficiency Rare metabolic condition – A No
Sodium phenylbutyrate Urea cycle disorders Rare metabolic condition A A* No
Sunitinib malate Renal cell carcinoma Solid tumour oncology – A No
Taliglucerase alfa Gaucher’s disease Rare metabolic condition S A No
Temoporfin Head and neck cancer Solid tumour oncology A – No
Temozolomide Anaplastic astrocytoma Solid tumour oncology A A Yes
Tocofersolan Vitamin E deficiency due to cholestasis Rare metabolic condition A – No
Tositumomab; iodine I 131
tositumomab
Non-Hodgkin’s lymphoma Haematological oncology – A No
Trabectedin Soft tissue sarcoma Solid tumour oncology A – No
Vismodegib Basal cell carcinoma Solid tumour oncology A A No
Vorinostat CTCL Haematological oncology S A No
Zinc Wilson’s disease (hepatolenticular degeneration) Rare metabolic condition A A* No
A, approved; A*, approved prior to 1999; S, submitted but not approved.
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Thus far, we have not discussed the appropriateness of
approvals without supporting RCT results. The com-
monly stated factors affecting the availability of evidence
are the rarity of the condition and the absence of
approved treatments. The appropriateness of these argu-
ments varies as comparative trials under rare conditions
are certainly challenging; however, they do not appear
to be consistent—for example canakinumab for
Cryopyrin-associated periodic syndrome, with a preva-
lence of <1/100 000, was studied in an RCT of 31
patients. Where there is no approved standard of care in
a terminal disease, in some cases (eg, alemtuzumab in
relapsed and refractory chronic lymphocytic leukaemia)
this justiﬁcation was used for the conduct of an uncon-
trolled study, whereas under similar conditions (pixan-
trone for aggressive relapsed B-cell non-Hodgkins
lymphoma) the manufacturer conducted a trial against
the treatment of physicians’ choice (from six widely
used off-label treatments). Even under the same condi-
tions, there is variability in the evidence base provided
by companies—Gaucher’s disease is a rare lysosomal
storage disorder and here taliglucerase alfa appears in
our sample without controlled trial results, yet velaglu-
cerase alfa included an active controlled trial in its devel-
opment programme.
Even where placebo RCTs are clearly unviable—
serious conditions without licensed treatments and a
well-established outcome (poisoning is the obvious
example); new treatments are often trialled against
standard care or as an addition to existing therapy. Such
controlled study designs have been used extensively in
the evaluation of novel treatments for schizophrenia
and, although not without challenges, could be used to
assess how a new treatment is performed.19
While much has been written on what level of effect
requires an RCT;4 in the treatments we identiﬁed, we
found that the persuasiveness of evidence is highly vari-
able. For example, imatinib in chronic myeloid leukae-
mia (CML) showed a response rate of 49% for major
cytogenetic response and 30% for complete cytogenetic
response in 532 patients, whereas omacetaxine, also in
CML, showed an 18.4% major cytogenetic response rate
and a 7.9% complete cytogenetic response in a trial of
76 patients. It is clear that there is a role for approval
without the support of RCT results; however, what an
acceptable data package should consist of does appear
to be inconsistent. This is even more apparent where
products must be assessed by organisations such as the
National Institute for Health and Care Excellence
(NICE) who has the role of estimating the difference in
outcomes between the new treatment and standard of
care; that is, demonstration of efﬁcacy alone is not suf-
ﬁcient.20 If the studies used to gain marketing author-
isation for products are also not able to provide
evidence for market access (ie, to convince payers that
such products represent value for money), then in
some cases, the use of uncontrolled trials may be
increasingly difﬁcult to justify as they do not provide
the evidence needed for the medicine to ultimately
treat patients.
The research that has been conducted on treatments
approved without RCT results (limited to oncology
drugs approved in the USA) indicates that the availabil-
ity of RCT evidence does not typically affect the likeli-
hood of remaining on the market, with some treatments
withdrawn for a lack of efﬁcacy or safety regardless of
whether randomised trial evidence was available.21
Those concerned about the lack of conﬁrmatory evi-
dence of efﬁcacy will ﬁnd little solace in this ﬁnding.
However, the reassessment of newly licensed drugs may
increase in importance with initiatives such as adaptive
licensing.22 The limited information we collected (on
ﬁve drugs approved on uncontrolled data by the FDA
and then approved by the EMA after the availability of
RCT results) suggest that current regulatory assessments
may well reach sound decisions in the absence of RCT
results, but this is limited by a small and selected sample.
Of particular concern, however, is the extensive use of
‘historical controls’ against which to compare outcomes
of trials. Previous research has highlighted that compari-
sons of this type are prone to exaggeration of the treat-
ment effect, with historical controls often performing far
worse than equivalent arms in clinical studies.23–25
CONCLUSION
Newly licensed pharmaceutical indications are fre-
quently approved without any controlled trial results,
particularly in solid and haematological malignancies.
While some agents showed such high levels of effective-
ness that an RCT is unlikely to have changed any deci-
sion, the level of evidence provided by companies to
support marketing authorisations does appear to be
inconsistent. In the more complex cases (particularly
those treatments not approved by one agency), it is not
always clear that the conduct of an RCT was impractical.
Although there appears to be a slight difference
between approvals in the EU and the USA (with the
FDA more likely to grant a positive approval in oncol-
ogy), the agencies broadly reach the same decisions.
However, the systematic differences in approval timing
are of particular interest and concern. We therefore
suggest that regulatory agencies should continue to har-
monise processes where practical (to reduce delays
between submissions). In parallel to this, given the fre-
quency at which uncontrolled studies occur, their role in
drug approval requires reappraisal, with formal guidance
on what represents an acceptable data package; this
should then be debated by regulators, companies and
physicians.
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